The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Alliance A222001: A randomized, double-blind, placebo controlled phase II study of oxybutynin versus placebo for the treatment of hot flashes in men receiving androgen deprivation therapy.
 
Brad J. Stish
Research Funding - Varian Medical Systems
 
Gina L. Mazza
No Relationships to Disclose
 
Jones T. Nauseef
Employment - Convergent Therapeutics
Honoraria - Pfizer
Consulting or Advisory Role - AIQ Solutions; Bayer; Pfizer
Travel, Accommodations, Expenses - Digital Science Press; Pfizer
 
Michael Sandon Humeniuk
No Relationships to Disclose
 
Thomas J. Smith
Employment - UpToDate
Patents, Royalties, Other Intellectual Property - Royalties from Oxford Textbook of Cancer Communication, co-editor.
 
Cindy Tofthagen
Stock and Other Ownership Interests - Trulieve; Trulieve
 
Dayssy Alexandra Diaz Pardo
No Relationships to Disclose
 
Christopher H. Chay
No Relationships to Disclose
 
Andrew Jonathan Huang
No Relationships to Disclose
 
Kushal Naha
No Relationships to Disclose
 
Scott T. Tagawa
Stock and Other Ownership Interests - Convergent Therapeutics
Consulting or Advisory Role - 4D Pharma; Abbvie; AIkido Pharma; Ambrx; Amgen; Astellas Pharma; Bayer; Bicycle Therapeutics; Blue Earth Diagnostics; Boston Scientific; Clarity Pharmaceuticals; Clovis Oncology; Convergent Therapeutics; Daiichi Sankyo; Dendreon; Endocyte; Exelixis; Genentech; Genomic Health; Gilead Sciences; Hookipa Pharma; Immunomedics; Janssen; Karyopharm Therapeutics; Medivation; Merck; Myovant Sciences; Novartis; Pfizer; POINT Biopharma; QED Therapeutics; Regeneron; Sanofi; Seagen; Telix Pharmaceuticals; Tolmar; TransThera Biosciences
Research Funding - Abbvie (Inst); Ambrx (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clarity Pharmaceuticals (Inst); Clovis Oncology (Inst); Dendreon (Inst); Endocyte (Inst); Exelixis (Inst); Genentech (Inst); Immunomedics (Inst); Inovio Pharmaceuticals (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Medivation (Inst); Merck (Inst); Millennium (Inst); Newlink Genetics (Inst); Novartis (Inst); POINT Biopharma (Inst); Progenics (Inst); Rexahn Pharmaceuticals (Inst); Sanofi (Inst); Stem CentRx (Inst)
Patents, Royalties, Other Intellectual Property - Patent Royalty from Immunomedics / Gilead
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; Immunomedics; Merck; Sanofi
(OPTIONAL) Uncompensated Relationships - ATLAB Pharma; Phosplatin Therapeutics
 
Selina Lai-ming Chow
No Relationships to Disclose
 
Lucile L. Adams-Campbell
No Relationships to Disclose
 
Paul J. Novotny
Stock and Other Ownership Interests - United Health Group
 
Charles L. Loprinzi
Consulting or Advisory Role - Bexion; Bexion; Bexion; Bexion; Denali Therapeutics; Denali Therapeutics; Disarm Therapeutics; Galendia; Genentech; Grunenthal; Hengrui Pharmaceutical ; Hengrui Pharmaceutical; Metys Pharmaceuticals; Metys Pharmaceuticals; Mitsubishi Tanabe Pharma; Neuropathix; Neuropathix; Neuropathix; NKMax; OnQuality Pharmaceuticals; Osmol Therapeutics; Veloxis; Veloxis; Vevro
Research Funding - Bristol-Myers Squibb (Inst)